18F-NaF and 18F-FDG as molecular probes in the evaluation of atherosclerosis

dc.contributor.authorMcKenney-Drake, Mikaela L.
dc.contributor.authorMoghbel, Mateen C.
dc.contributor.authorPaydary, Koosha
dc.contributor.authorAlloosh, Mouhamad
dc.contributor.authorHoushmand, Sina
dc.contributor.authorMoe, Sharon
dc.contributor.authorSalavati, Ali
dc.contributor.authorSturek, Jeffrey M.
dc.contributor.authorTerrito, Paul R.
dc.contributor.authorWeaver, Connie
dc.contributor.authorWerner, Thomas J.
dc.contributor.authorHøilund-Carlsen, Poul Flemming
dc.contributor.authorSturek, Michael
dc.contributor.authorAlavi, Abass
dc.contributor.departmentCellular and Integrative Physiology, School of Medicineen_US
dc.date.accessioned2019-05-13T18:26:24Z
dc.date.available2019-05-13T18:26:24Z
dc.date.issued2018-11
dc.description.abstractThe early detection of atherosclerotic disease is vital to the effective prevention and management of life-threatening cardiovascular events such as myocardial infarctions and cerebrovascular accidents. Given the potential for positron emission tomography (PET) to visualize atherosclerosis earlier in the disease process than anatomic imaging modalities such as computed tomography (CT), this application of PET imaging has been the focus of intense scientific inquiry. Although 18F-FDG has historically been the most widely studied PET radiotracer in this domain, there is a growing body of evidence that 18F-NaF holds significant diagnostic and prognostic value as well. In this article, we review the existing literature on the application of 18F-FDG and 18F-NaF as PET probes in atherosclerosis and present the findings of original animal and human studies that have examined how well 18F-NaF uptake correlates with vascular calcification and cardiovascular risk.en_US
dc.identifier.citationMcKenney-Drake, M. L., Moghbel, M. C., Paydary, K., Alloosh, M., Houshmand, S., Moe, S., … Alavi, A. (2018). 18F-NaF and 18F-FDG as molecular probes in the evaluation of atherosclerosis. European journal of nuclear medicine and molecular imaging, 45(12), 2190–2200. doi:10.1007/s00259-018-4078-0en_US
dc.identifier.urihttps://hdl.handle.net/1805/19258
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.relation.isversionof10.1007/s00259-018-4078-0en_US
dc.relation.journalEuropean Journal of Nuclear Medicine and Molecular Imagingen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.sourcePMCen_US
dc.subjectAtherosclerosisen_US
dc.subject18F-FDGen_US
dc.subject18F-NaFen_US
dc.subjectCalcificationen_US
dc.subjectCardiovascular disease quantificationen_US
dc.subjectGlobal assessment of cardiac diseaseen_US
dc.title18F-NaF and 18F-FDG as molecular probes in the evaluation of atherosclerosisen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
259_2018_Article_4078.pdf
Size:
4.65 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: